Get the Stockscreener App
11.83
1.98%
0.23
Eyepoint Pharmaceuticals Inc stock is traded at $11.83, with a volume of 683.12K.
It is up +1.98% in the last 24 hours and up +13.21% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$11.60
Open:
$11.6
24h Volume:
683.12K
Relative Volume:
0.89
Market Cap:
$815.41M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-6.50
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+6.67%
1M Performance:
+13.21%
6M Performance:
+92.36%
1Y Performance:
+31.44%
1-Day Range:
$11.40
$12.14
1-Week Range:
$10.84
$12.14
52-Week Range:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
11.83 | 780.95M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
EyePoint Pharmaceuticals Inc. Bounces Off Moving Average SupportJuly 2025 Retail & Growth Focused Entry Point Reports - beatles.ru
EyePoint Pharmaceuticals Inc. stock daily chart insightsTrade Risk Report & AI Driven Stock Reports - Newser
Short interest data insights for EyePoint Pharmaceuticals Inc.Trade Exit Summary & Low Risk High Win Rate Picks - Newser
Sector ETF performance correlation with EyePoint Pharmaceuticals Inc.Quarterly Trade Review & High Conviction Buy Zone Alerts - Newser
Strategies to average down on EyePoint Pharmaceuticals Inc.2025 Trading Recap & Low Risk High Reward Ideas - Newser
Quantitative breakdown of EyePoint Pharmaceuticals Inc. recent moveMarket Activity Summary & Smart Allocation Stock Tips - Newser
Published on: 2025-08-19 03:16:46 - Newser
EyePoint Reports Inducement Grants Under NASDAQ Listing - MSN
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
18,000 Stock Options at $11.09: EyePoint Pharmaceuticals Awards Inducement Grants to Key New Hires - Stock Titan
Live market analysis of EyePoint Pharmaceuticals Inc.Risk Management & Weekly Setup with High ROI Potential - Newser
Why EyePoint Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Drop Watch & Growth Focused Stock Reports - Newser
News impact scoring models applied to EyePoint Pharmaceuticals Inc.July 2025 Volume & Community Consensus Picks - Newser
Can momentum traders help lift EyePoint Pharmaceuticals Inc.Wall Street Watch & Risk Adjusted Buy/Sell Alerts - Newser
What to do if you’re stuck in EyePoint Pharmaceuticals Inc.Portfolio Performance Summary & Weekly Market Pulse Alerts - Newser
Is EyePoint Pharmaceuticals Inc. still worth holding after the dipWeekly Market Outlook & Intraday High Probability Setup Alerts - Newser
Signal strength of EyePoint Pharmaceuticals Inc. stock in tech scannersJuly 2025 Levels & Low Risk High Reward Trade Ideas - Newser
Will EyePoint Pharmaceuticals Inc. Reverse From Oversold ConditionsQuarterly Profit Summary & Low Risk Investment Opportunities - sundaytimes.kr
How EyePoint Pharmaceuticals Inc. stock reacts to Fed policy changesQuarterly Portfolio Review & Consistent Growth Equity Picks - Newser
Key metrics from EyePoint Pharmaceuticals Inc.’s quarterly dataInsider Selling & Expert-Curated Trade Recommendations - Newser
What is the next catalyst for EyePoint Pharmaceuticals Inc.Rate Hike & Technical Pattern Recognition Alerts - thegnnews.com
What is EyePoint Pharmaceuticals Inc.’s market position2025 Momentum Check & Real-Time Buy Zone Alerts - thegnnews.com
EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy - MSN
Real time alert setup for EyePoint Pharmaceuticals Inc. performancePortfolio Update Report & Weekly High Potential Stock Alerts - Newser
Why is EyePoint Pharmaceuticals Inc. stock going downTrend Reversal & Weekly Momentum Picks - thegnnews.com
What recovery options are there for EyePoint Pharmaceuticals Inc.July 2025 Weekly Recap & Technical Buy Zone Confirmations - Newser
How to interpret RSI for EyePoint Pharmaceuticals Inc. stock2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
EyePoint Pharmaceuticals stock price target raised to $28 at Mizuho - Investing.com
EyePoint Pharmaceuticals stock price target raised to $28 at Mizuho By Investing.com - Investing.com Nigeria
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Raises Target Price to $28 - 富途牛牛
Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating - MarketScreener
EyePoint at H.C. Wainwright: Strategic Insights on Wet AMD Trials By Investing.com - Investing.com Canada
EyePoint (EYPT) Q2 Revenue Drops 44% - AOL.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - MSN
XTX Topco Ltd Acquires New Stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $41 - 富途牛牛
Zurcher Kantonalbank Zurich Cantonalbank Has $122,000 Stock Position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Completes Enrollment for Phase 3 Trials - MSN
Published on: 2025-08-10 17:36:12 - beatles.ru
Analysts Have Lowered Expectations For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Its Latest Results - 富途牛牛
EyePoint Pharmaceuticals Sees Analyst Expectations Lowered After Disappointing Q2 Results - AInvest
How did EYPT's revenue streams evolve in Q4 2024? - AInvest
Chardan Capital Reiterates "Buy" Rating for EyePoint Pharmaceuticals with $27 Price Target - AInvest
EyePoint Pharma: Clinical Progress Amid Financial Hurdles - AInvest
EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment - MSN
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
EyePoint Pharmaceuticals (EYPT): Chardan Capital Maintains "Buy" Rating | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected at $6.63 Million - AInvest
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyepoint Pharmaceuticals Inc Stock (EYPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Jul 10 '25 |
Option Exercise |
0.00 |
11,111 |
0 |
216,547 |
| Duker Jay S. | President and CEO |
Jul 10 '25 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Elston George | Chief Financial Officer |
May 25 '25 |
Option Exercise |
0.00 |
7,500 |
0 |
83,050 |
| Zaderej Karen L. | Director |
May 19 '25 |
Buy |
5.99 |
5,000 |
29,950 |
36,500 |
| Zaderej Karen L. | Director |
May 16 '25 |
Buy |
5.81 |
5,000 |
29,050 |
31,500 |
| Zaderej Karen L. | Director |
May 15 '25 |
Buy |
5.47 |
5,000 |
27,350 |
26,500 |
| Zaderej Karen L. | Director |
May 14 '25 |
Buy |
5.42 |
5,000 |
27,100 |
21,500 |
| Elston George | Chief Financial Officer |
Feb 09 '25 |
Option Exercise |
0.00 |
5,834 |
0 |
75,550 |
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):